专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO0103744A3 RECOMBINANT PARAINFLUENZA VIRUS VACCINES ATTENUATED BY DELETION OR ABLATION OF THE C, D OR V GENES 审中-公开
标题翻译：通过C，D或V基因的删除或消除而破坏的重组腺病毒病毒疫苗
公开(公告)号：WO0103744A3
公开(公告)日：2001-09-13
申请号：PCT/US0018523
申请日：2000-07-06
申请人： US GOV HEALTH & HUMAN SERV , DURBIN ANNA P , COLLINS PETER L , MURPHY BRIAN R
发明人： DURBIN ANNA P , COLLINS PETER L , MURPHY BRIAN R
IPC分类号： C12N15/09 , A61K9/12 , A61K39/00 , A61K39/102 , A61K48/00 , A61P31/16 , C07K14/115 , C12N7/00 , C12N7/04 , C12N15/45 , A61K39/155 , C12N15/11
CPC分类号： C12N7/00 , A61K39/00 , A61K2039/522 , C07K14/005 , C12N2760/18622 , C12N2760/18643 , C12N2760/18661
摘要： Recombinant parainfluenza virus (PIV) are provided in which expression of the C, D and/or V translational open reading frame(s) (ORFs) is reduced or ablated to yield novel PIV vaccine candidates. Expression of the C, D and/or V ORF(s) is reduced or ablated by modifying a recombinant PIV genome or antigenome, for example by introduction of a stop codon, by a mutation in an RNA editing site, by a mutation that alters the amino acid specified by an initiation codon, or by a frame shift mutation in the targeted ORF(s). Alternatively, the C, D and/or V ORF(s) is deleted in whole or in part to render the protein(s) encoded thereby partially or entirely non-functional or to disrupt protein expression altogether. C, D and/or V ORF(s) deletion and knock out mutants possess highly desirable phenotypic characteristics for vaccine development. These deletion and knock out mutations changes specify one or more desired phenotypic changes in the resulting virus or subviral particle. Vaccine candidates are generated that show a change in viral growth characteristics, attenuation, plaque size, and/or a change in cytopathogenicity, among other novel phenotypes. A variety of additional mutations and nucleotide modifications are provided within the C, D and/or V ORF(s) deletion or ablation mutant PIV of the invention to yield desired phenotypic and structural effects.
摘要翻译：提供了重组副流感病毒（PIV），其中C，D和/或V翻译开放阅读框（ORF）的表达被降低或消融以产生新型PIV疫苗候选物。 C，D和/或V ORF的表达通过修饰重组PIV基因组或反义基因组，例如通过引入终止密码子，通过RNA编辑位点中的突变，通过改变的突变来降低或消除由起始密码子指定的氨基酸或靶向ORF中的帧位移突变。或者，C，D和/或V ORF全部或部分缺失，以使由此编码的蛋白质部分或完全不起作用或完全破坏蛋白质表达。 C，D和/或V ORF（s）缺失和敲除突变体对疫苗开发具有非常需要的表型特征。这些缺失和敲除突变变化指定了所得病毒或亚病毒颗粒中的一种或多种期望的表型变化。产生疫苗候选物，其显示病毒生长特征，衰减，斑块大小和/或细胞致病性变化以及其他新型表型之间的变化。本发明的C，D和/或V ORF缺失或消融突变体PIV中提供了多种其它突变和核苷酸修饰，以产生所需的表型和结构效果。

2. 发明申请

WO2010003032A8 RECOMBINANT HUMAN PARAINFLUENZA TYPE 1 VIRUSES (HPIV1S) CONTAINING MUTATIONS IN OR DELETION OF THE C PROTEIN ARE ATTENUATED IN AFRICAN GREEN MONKEYS AND IN CILIATED HUMAN AIRWAY EPITHELIAL CELLS AND ARE POTENTIAL VACCINE CANDIDATES FOR HPIV1 审中-公开
公开(公告)号：WO2010003032A8
公开(公告)日：2010-03-11
申请号：PCT/US2009049461
申请日：2009-07-01
申请人： US GOV HEALTH & HUMAN SERV , BARTLETT EMMALENE , COLLINS PETER L , SKIADOPOULOS MARIO H , MURPHY BRIAN R
发明人： BARTLETT EMMALENE , COLLINS PETER L , SKIADOPOULOS MARIO H , MURPHY BRIAN R
IPC分类号： C07K14/005
CPC分类号： C12N7/00 , A61K39/12 , A61K39/155 , A61K2039/5254 , A61K2039/543 , C12N2760/18634 , C12N2760/18661
摘要： Two recently characterized live attenuated HPIV1 vaccine candidates, rHPIV1-CR84G/ ?170HNT553ALY942A and rHPIV1-CR84G/? 170HNT553AL? 1710-11, which contain temperature sensitive (ts) attenuating (att) and non-ts att mutations, were evaluated in a Human Airway Epithelium (HAE) model culture system and in vivo in African Green monkeys (AGM). The vaccine candidates were highly restricted in growth in HAE at permissive (32 o C) and restrictive (37 o C) temperatures. The viruses grew slightly better at 37 o C than at 32 oC, and rHPIV1-CR84G/ ?170HNT553ALY942A was less attenuated than rHPIV1-CR84G/ ?170HNT553AL ?1710-11. The level of replication in HAE correlated with that observed in African Green monkeys, suggesting that the HAE model is useful as a tool for pre-clinical evaluation of HPIV1 vaccines. A live attenuated HPIV1 vaccine candidate having a normal P/C gene structure of overlapping P and C open reading frames, but does not express any functional C protein, is found to highly attenuated in AGMs, and provides a significant immune response in AGMs.

3. 发明申请

WO0104335A3 HUMAN-BOVINE CHIMERIC RESPIRATORY SYNCYTIAL VIRUS VACCINES 审中-公开
标题翻译：人类猪流感呼吸道感染病毒疫苗
公开(公告)号：WO0104335A3
公开(公告)日：2002-12-19
申请号：PCT/US0017755
申请日：2000-06-23
申请人： US GOV HEALTH & HUMAN SERV , BUCHHOLZ URSULA , COLLINS PETER L , MURPHY BRIAN R , WHITEHEAD STEPHEN S , KREMPL CHRISTINE D
发明人： BUCHHOLZ URSULA , COLLINS PETER L , MURPHY BRIAN R , WHITEHEAD STEPHEN S , KREMPL CHRISTINE D
IPC分类号： C12N15/09 , A61K39/00 , A61K39/12 , A61P11/00 , C07K14/14 , C12N7/00 , C12N7/04 , C12N15/86 , C12R1/93 , A61K38/17 , C12N15/62
CPC分类号： C12N7/00 , A61K39/00 , A61K39/12 , A61K39/155 , A61K2039/5254 , A61K2039/5256 , A61K2039/544 , C07K14/005 , C07K2319/00 , C12N15/86 , C12N2760/18522 , C12N2760/18534 , C12N2760/18543 , C12N2760/18561 , C12N2840/203
摘要： Chimeric human-bovine respiratory syncytial virus (RSV) are infectious and attenuated in humans and other mammals and useful in vaccine formulations for eliciting an anti-RSV immune response. Also provided are isolated polynucleotide molecules and vectors incorporating a chimeric RSV genome or antigenome which includes a partial or complete human or bovine RSV "background" genome or antigenome combined or integrated with one or more heterologous gene(s) or genome segment(s) of a different RSV strain. Chimeric human-bovine RSV of the invention include a partial or complete "background" RSV genome or antigenome derived from or patterned after a human or bovine RSV strain or subgroup virus combined with one or more heterologous gene(s) or genome segment(s) of a different RSV strain or subgroup virus to form the human-bovine chimeric RSV genome or antigenome. In preferred aspects of the invention, chimeric RSV incorporate a partial or complete bovine RSV background genome or antigenome combined with one or more heterologous gene(s) or genome segment(s) from a human RSV. Genes of interest include any of the NS1, NS2, N, P, M, SH, M2(ORF1), M2(ORF2), L, F or G genes or a genome segment including a protein or portion thereof. A variety of additional mutations and nucleotide modifications are provided within the human-bovine chimeric RSV of the invention to yield desired phenotypic and structural effects.
摘要翻译：嵌合人 - 牛呼吸道合胞病毒（RSV）在人类和其他哺乳动物中具有感染性和减毒性，并且可用于引发抗RSV免疫应答的疫苗制剂中。还提供了分离的多核苷酸分子和掺入嵌合RSV基因组或抗原组的载体，其包括部分或完整的人或牛RSV“背景”基因组或与一个或多个异源基因或基因组片段不同的RSV菌株。本发明的嵌合人类牛RSV包括部分或完整的“背景”RSV基因组或在与一个或多个异源基因或基因组片段组合的人或牛RSV病毒株或亚组病毒之后衍生或构图的部分或完整的“背景” 的不同RSV株或亚组病毒形成人 - 牛嵌合RSV基因组或抗原组。在本发明的优选方面，嵌合RSV包含与来自人RSV的一个或多个异源基因或基因组片段组合的部分或完整的牛RSV背景基因组或反向异构体。感兴趣的基因包括任何NS1，NS2，N，P，M，SH，M2（ORF1），M2（ORF2），L，F或G基因或包含蛋白质或其部分的基因组片段。在本发明的人 - 牛嵌合RSV内提供了多种额外的突变和核苷酸修饰，以产生所需的表型和结构效果。

4. 发明申请

WO2010003032A3 RECOMBINANT HUMAN PARAINFLUENZA TYPE 1 VIRUSES (HPIV1S) CONTAINING MUTATIONS IN OR DELETION OF THE C PROTEIN ARE ATTENUATED IN AFRICAN GREEN MONKEYS AND IN CILIATED HUMAN AIRWAY EPITHELIAL CELLS AND ARE POTENTIAL VACCINE CANDIDATES FOR HPIV1 审中-公开
标题翻译：包含突变或缺失C蛋白的重组人类嗜血菌1型病毒（HPIV1S）在非洲绿色猴子和人类睫状体上皮细胞中减毒并且是HPIV1的潜在疫苗候选者
公开(公告)号：WO2010003032A3
公开(公告)日：2010-08-12
申请号：PCT/US2009049461
申请日：2009-07-01
申请人： US GOV HEALTH & HUMAN SERV , BARTLETT EMMALENE , COLLINS PETER L , SKIADOPOULOS MARIO H , MURPHY BRIAN R
发明人： BARTLETT EMMALENE , COLLINS PETER L , SKIADOPOULOS MARIO H , MURPHY BRIAN R
IPC分类号： C07K14/005
CPC分类号： C12N7/00 , A61K39/12 , A61K39/155 , A61K2039/5254 , A61K2039/543 , C12N2760/18634 , C12N2760/18661
摘要： Two recently characterized live attenuated HPIV1 vaccine candidates, rHPIV1-CR84G/ ?170HNT553ALY942A and rHPIV1-CR84G/? 170HNT553AL? 1710-11, which contain temperature sensitive (ts) attenuating (att) and non-ts att mutations, were evaluated in a Human Airway Epithelium (HAE) model culture system and in vivo in African Green monkeys (AGM). The vaccine candidates were highly restricted in growth in HAE at permissive (32 o C) and restrictive (37 o C) temperatures. The viruses grew slightly better at 37 o C than at 32 oC, and rHPIV1-CR84G/ ?170HNT553ALY942A was less attenuated than rHPIV1-CR84G/ ?170HNT553AL ?1710-11. The level of replication in HAE correlated with that observed in African Green monkeys, suggesting that the HAE model is useful as a tool for pre-clinical evaluation of HPIV1 vaccines. A live attenuated HPIV1 vaccine candidate having a normal P/C gene structure of overlapping P and C open reading frames, but does not express any functional C protein, is found to highly attenuated in AGMs, and provides a significant immune response in AGMs.
摘要翻译：最近有两种特征性活减毒HPIV1候选疫苗，rHPIV1-CR84G /？170HNT553ALY942A和rHPIV1-CR84G /？ 170HNT553AL？在人类呼吸道上皮细胞（HAE）模型培养系统中和体内非洲绿猴（AGM）中评估含有温度敏感性（ts）减弱（att）和非ts att突变的1710-11。候选疫苗高度限制HAE在宽容（32℃）和限制性（37℃）温度下的生长。病毒在37℃时比在32℃时稍微好些，rHPIV1-CR84G /Δ170HNT553ALY942A比rHPIV1-CR84G /Δ170HNT553ALΔ1710-11弱。 HAE中的复制水平与在非洲绿猴中观察到的复制水平相关，表明HAE模型可用作HPIV1疫苗的临床前评估的工具。发现具有重叠的P和C开放阅读框但不表达任何功能性C蛋白的正常P / C基因结构的活的减毒HPIV1疫苗候选物在AGM中高度减毒，并且在AGM中提供显着的免疫应答。

5. 发明申请

WO2007120120A2 ATTENUATED HUMAN PARAINFLUENZA VIRUS, METHODS AND USES THEREOF 审中-公开
标题翻译：衰老的人类流行性感冒病毒，其方法和用途
公开(公告)号：WO2007120120A2
公开(公告)日：2007-10-25
申请号：PCT/US2006000666
申请日：2006-01-10
申请人： US GOV HEALTH & HUMAN SERV , SKIADOPOULOS MARIO H , MURPHY BRIAN R , COLLINS PETER L , NOLAN SHEILA
发明人： SKIADOPOULOS MARIO H , MURPHY BRIAN R , COLLINS PETER L , NOLAN SHEILA
IPC分类号： C12N7/00
CPC分类号： C07K14/005 , A61K2039/5254 , A61K2039/5256 , C12N7/00 , C12N15/86 , C12N2760/18722 , C12N2760/18743 , C12N2760/18761
摘要： The invention provides self replicating infectious recombinant paramyxoviruses. The recombinant paramyxovirus preferably have one or more attenuating mutations. In some embodiments, the recombinant paramyxovirus has a separate variant polynucleotide encoding a P protein and a separate monocistronic polynucleotide encoding a V protein. In some embodiments, recombinant paramyxovirus have at least one temperature sensitive mutation and one non-temperature sensitive mutation. Also provided are compositions and methods for using the recombinant paramyxoviruses as described herein.
摘要翻译：本发明提供了自我复制的感染性重组副粘病毒。重组副粘病毒优选具有一个或多个减毒突变。在一些实施方案中，重组副粘病毒具有编码P蛋白的单独变体多核苷酸和编码V蛋白的分离的单顺反子多核苷酸。在一些实施方案中，重组副粘病毒具有至少一个温度敏感突变和一个非温度敏感突变。还提供了使用如本文所述的重组副粘病毒的组合物和方法。

6. 发明申请

WO0104335A8 HUMAN-BOVINE CHIMERIC RESPIRATORY SYNCYTIAL VIRUS VACCINES 审中-公开
标题翻译：人类猪流感呼吸道感染病毒疫苗
公开(公告)号：WO0104335A8
公开(公告)日：2003-02-06
申请号：PCT/US0017755
申请日：2000-06-23
申请人： US GOV HEALTH & HUMAN SERV , BUCHHOLZ URSULA , COLLINS PETER L , MURPHY BRIAN R , WHITEHEAD STEPHEN S , KREMPL CHRISTINE D
发明人： BUCHHOLZ URSULA , COLLINS PETER L , MURPHY BRIAN R , WHITEHEAD STEPHEN S , KREMPL CHRISTINE D
IPC分类号： C12N15/09 , A61K39/00 , A61K39/12 , A61P11/00 , C07K14/14 , C12N7/00 , C12N7/04 , C12N15/86 , C12R1/93 , A61K38/17 , C12N15/62
CPC分类号： C12N7/00 , A61K39/00 , A61K39/12 , A61K39/155 , A61K2039/5254 , A61K2039/5256 , A61K2039/544 , C07K14/005 , C07K2319/00 , C12N15/86 , C12N2760/18522 , C12N2760/18534 , C12N2760/18543 , C12N2760/18561 , C12N2840/203
摘要： Chimeric human-bovine respiratory syncytial virus (RSV) are infectious and attenuated in humans and other mammals and useful in vaccine formulations for eliciting an anti-RSV immune response. Also provided are isolated polynucleotide molecules and vectors incorporating a chimeric RSV genome or antigenome which includes a partial or complete human or bovine RSV "background" genome or antigenome combined or integrated with one or more heterologous gene(s) or genome segment(s) of a different RSV strain. Chimeric human-bovine RSV of the invention include a partial or complete "background" RSV genome or antigenome derived from or patterned after a human or bovine RSV strain or subgroup virus combined with one or more heterologous gene(s) or genome segment(s) of a different RSV strain or subgroup virus to form the human-bovine chimeric RSV genome or antigenome. In preferred aspects of the invention, chimeric RSV incorporate a partial or complete bovine RSV background genome or antigenome combined with one or more heterologous gene(s) or genome segment(s) from a human RSV. Genes of interest include any of the NS1, NS2, N, P, M, SH, M2(ORF1), M2(ORF2), L, F or G genes or a genome segment including a protein or portion thereof. A variety of additional mutations and nucleotide modifications are provided within the human-bovine chimeric RSV of the invention to yield desired phenotypic and structural effects.
摘要翻译：嵌合人 - 牛呼吸道合胞病毒（RSV）在人类和其他哺乳动物中具有感染性和减毒性，并且可用于引发抗RSV免疫应答的疫苗制剂中。还提供了分离的多核苷酸分子和掺入嵌合RSV基因组或抗原组的载体，其包括部分或完整的人或牛RSV“背景”基因组或与一个或多个异源基因或基因组片段不同的RSV菌株。本发明的嵌合人类牛RSV包括部分或完整的“背景”RSV基因组或在与一个或多个异源基因或基因组片段组合的人或牛RSV病毒株或亚组病毒之后衍生或构图的部分或完整的“背景” 的不同RSV株或亚组病毒形成人 - 牛嵌合RSV基因组或抗原组。在本发明的优选方面，嵌合RSV包含与来自人RSV的一个或多个异源基因或基因组片段组合的部分或完整的牛RSV背景基因组或反向异构体。感兴趣的基因包括任何NS1，NS2，N，P，M，SH，M2（ORF1），M2（ORF2），L，F或G基因或包含蛋白质或其部分的基因组片段。在本发明的人 - 牛嵌合RSV内提供了多种额外的突变和核苷酸修饰，以产生所需的表型和结构效果。

7. 发明申请

WO0142445A3 USE OF RECOMBINANT PARAINFLUENZA VIRUSES (PIVs) AS VECTORS TO PROTECT AGAINST INFECTION AND DISEASE CAUSED BY PIV AND OTHER HUMAN PATHOGENS 审中-公开
标题翻译：使用重组对虾流感病毒（PIV）作为保护对抗由PIV和其他人类病原体引起的感染和疾病的媒介
公开(公告)号：WO0142445A3
公开(公告)日：2001-11-29
申请号：PCT/US0033293
申请日：2000-12-08
申请人： US HEALTH , MURPHY BRIAN R , COLLINS PETER L , SCHMIDT ALEXANDER C , DURBIN ANNA P , SKIADOPOULOS MARIO H , TAO TAO
发明人： MURPHY BRIAN R , COLLINS PETER L , SCHMIDT ALEXANDER C , DURBIN ANNA P , SKIADOPOULOS MARIO H , TAO TAO
IPC分类号： C12N15/09 , A61K39/00 , A61K39/12 , A61K39/145 , A61K39/205 , A61K39/245 , A61K48/00 , A61P37/02 , C07K14/115 , C12N7/00 , C12N15/86 , C12R1/93 , C12N15/45 , A61K39/155 , C12N5/10 , C12N15/62
CPC分类号： C07K14/005 , A61K39/00 , A61K2039/5256 , C12N15/86 , C12N2760/18622 , C12N2760/18643
摘要： Chimeric parainfluenza viruses (PIVs) are provided that incorporate a PIV vector genome or antigenome and one or more antigenic determinant(s) of a heterologous PIV or non-PIV pathogen. These chimeric viruses are infectious and attenuated in humans and other mammals and are useful in vaccine formulations for eliciting an immune responses against one or more PIVs, or against a PIV and non-PIV pathogen. Also provided are isolated polynucleotide molecules and vectors incorporating a chimeric PIV genome or antigenome which includes a partial or complete PIV vector genome or antigenome combined or integrated with one or more heterologous gene(s) or genome segment(s) encoding antigenic determinant(s) of a heterologous PIV or non-PIV pathogen. In preferred aspects of the invention, chimeric PIV incorporate a partial or complete human, bovine, or human-bovine chimeric, PIV vector genome or antigenome combined with one or more heterologous gene(s) or genome segment(s) from a heterologous PIV or non-PIV pathogen, wherein the chimeric virus is attenuated for use as a vaccine agent by any of a variety of mutations and nucleotide modifications introduced into the chimeric genome or antigenome.
摘要翻译：提供嵌合副流感病毒（PIV），其包含PIV载体基因组或反基因组以及异源PIV或非PIV病原体的一种或多种抗原决定簇。这些嵌合病毒在人和其他哺乳动物中是感染性和减毒性的，并且可用于引发针对一种或多种PIV或针对PIV和非PIV病原体的免疫应答的疫苗制剂。还提供了分离的多核苷酸分子和掺入嵌合PIV基因组或反基因组的载体，所述嵌合PIV基因组或反基因组包含与编码抗原决定簇的一个或多个异源基因或基因组区段组合或整合的部分或完整PIV载体基因组或反基因组，的异源PIV或非PIV病原体。在本发明的优选方面，嵌合PIV包含与来自异源PIV的一个或多个异源基因或基因组区段结合的部分或完整人，牛或人 - 牛嵌合PIV载体基因组或反基因组，或非PIV病原体，其中通过引入嵌合基因组或反基因组中的任何多种突变和核苷酸修饰，嵌合病毒减毒用作疫苗剂。

8. 发明申请

WO0061737A3 Production of attenuated negative stranded RNA virus vaccines 审中-公开
标题翻译：减毒负链RNA病毒疫苗的生产
公开(公告)号：WO0061737A3
公开(公告)日：2001-08-23
申请号：PCT/US0009695
申请日：2000-04-12
申请人： US GOV HEALTH & HUMAN SERV
发明人： MURPHY BRIAN R , COLLINS PETER L , DURBIN ANNA P , SKIADOPOULOS MARIO H
IPC分类号： C12N15/09 , A61K39/155 , A61P31/14 , C07K14/115 , C07K14/135 , C12N7/00 , C12N7/04 , C12N15/00 , C12R1/93 , C12N15/86
CPC分类号： C07K14/005 , A61K2039/5254 , C12N7/00 , C12N2760/18622 , C12N2760/18643 , C12N2760/18661 , C12N2760/18822
摘要： Attenuated, recombinant negative stranded RNA viruses suitable for vaccine use are produced from one or more isolated polynucleotide molecules encoding the virus. A recombinant genome or antigenome of the subject virus is modified to encode a mutation within a recombinant protein of the virus at one or more amino acid positions(s) corresponding to a site of an attenuating mutation in a heterologous, mutant negative stranded RNA virus. A similar attenuating mutation as identified in the heterologous negative stranded RNA virus is thus incorporated at a corresponding site within the recombinant virus to confer an attenuated phenotype on the recombinant virus. The attenuating mutation incorporated in the recombinant virus may be identical or conservative in relation to the attenuating mutation identified in the heterologous, mutant virus. By the transfer of mutations into recombinant negative stranded RNA viruses in this manner, candidate vaccine viruses are engineered to elicit a desired immune response against a subject virus in a host susceptible to infection thereby.

9. 发明公开

EP1438399A4 PARAMYXOVIRUSES AS GENE TRANSFER VECTORS TO LUNG CELLS 审中-公开
标题翻译：副粘病毒作为在肺细胞基因转移载体
公开(公告)号：EP1438399A4
公开(公告)日：2005-09-14
申请号：EP02763762
申请日：2002-09-27
申请人： UNIV NORTH CAROLINA , RUSH PRESBYTERIAN ST LUKE , US GOV HEALTH & HUMAN SERV
发明人： PICKLES RAYMOND J , ZHANG LIQUN , PEEPLES MARK E , COLLINS PETER L , OLSEN JOHN C
IPC分类号： A61K48/00 , C07K14/47 , C12N7/00 , C12N15/09 , C12N15/86 , C12N15/867 , C12N15/00
CPC分类号： C07K14/4712 , C12N15/86 , C12N2740/15043 , C12N2740/15045 , C12N2760/18522 , C12N2760/18622 , C12N2810/6072

10. 发明申请

WO2005014626A3 RECOMBINANT HUMAN METAPNEUMOVIRUS AND ITS USE 审中-公开
标题翻译：重组人类髓母细胞瘤及其应用
公开(公告)号：WO2005014626A3
公开(公告)日：2005-04-28
申请号：PCT/US2004005881
申请日：2004-02-27
申请人： US HEALTH , COLLINS PETER L , BIACCHESI STEPHANE , BUCHHOLZ URSULA , SKIADOPOULOS MARIO H , MURPHY BRIAN R
发明人： COLLINS PETER L , BIACCHESI STEPHANE , BUCHHOLZ URSULA , SKIADOPOULOS MARIO H , MURPHY BRIAN R
IPC分类号： C12N7/04 , C12N15/86 , C07K14/115 , A61K39/155
CPC分类号： A61K39/155 , A61K39/12 , A61K2039/5254 , A61K2039/5256 , A61K2039/70 , C12N7/00 , C12N15/86 , C12N2760/18334 , C12N2760/18343 , C12N2760/18351 , C12N2760/18361 , C12N2760/18362 , C12N2760/18634 , C12N2760/18643
摘要： Recombinant HMPV (rHMPV) and related immunogenic compositions and methods are provided. The rHMPVs, including chimeric and HMPV vector viruses, provided according to the current disclosure are infectious and attenuated in permissive mammalian subjects, including humans. The rHMPVs are useful in immunogenic compositions for eliciting an immune response against HPIV, against one or more non-HMPV pathogens, or against a HMPV and a non-HMPV pathogen. Also provided are isolated polynucloetide molecules and vectors incorporating a recombinant HMPV genome or antigenome.
摘要翻译：提供了重组HMPV（rHMPV）和相关的免疫原性组合物和方法。根据本公开提供的rHMPV包括嵌合和HMPV载体病毒在许可的哺乳动物受试者包括人中是感染性和减毒的。 rHMPV可用于免疫原性组合物中以引发针对HPIV，针对一种或多种非HMPV病原体或针对HMPV和非HMPV病原体的免疫应答。还提供了分离的多聚核苷酸分子和载有重组HMPV基因组或反基因组的载体。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式